US20060035924A1 - Daily melatonin dosing units - Google Patents
Daily melatonin dosing units Download PDFInfo
- Publication number
- US20060035924A1 US20060035924A1 US10/533,517 US53351705A US2006035924A1 US 20060035924 A1 US20060035924 A1 US 20060035924A1 US 53351705 A US53351705 A US 53351705A US 2006035924 A1 US2006035924 A1 US 2006035924A1
- Authority
- US
- United States
- Prior art keywords
- container
- melatonin
- agent
- derivative
- arrangement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
Definitions
- the present invention relates to a disposable container for a medicament or cosmetic agent for topical application, containing a single dose of melatonin or of a melatonin derivative which corresponds to a locally effective dose but which does not cause any systemic effect.
- Melatonin-containing agents can be used for various medical and cosmetic purposes.
- the document DE 101 10 418.9 discloses melatonin-containing compositions for topical application on the skin and in the hair.
- the subject of the present invention is a disposable container for a medicament or cosmetic agent for topical application, containing a single dose of melatonin or of a melatonin derivative which corresponds to a locally effective dose but which does not cause any systemic effect.
- the disposable container according to the invention permits application of a dose of melatonin or of a melatonin derivative which is locally effective but which causes no undesired change in the normal melatonin plasma level.
- the single dose of melatonin or of melatonin derivative which is applied according to the invention causes no significant elevation of the melatonin plasma level for example.
- melatonin or melatonin derivative includes melatonin and/or melatonin derivatives and salts, esters or complexes thereof.
- Preferred melatonin derivatives include, for example, 5-methoxytryptamine, 5-methoxytryptophan, 5-methoxytryptophol, 5-methoxy-indole-3-acetic acid and 6-hydroxymelatonin.
- the single dose according to the invention represents a dose which permits a positive cosmetic and/or therapeutic effect without significant changes in the plasma level.
- a single dose of from approximately 0.001 to approximately 1.0 mg of melatonin is preferred, and more preferably a single dose of from approximately 0.01 to approximately 0.2 mg of melatonin.
- a single dose can be applied once or several times daily.
- the single dose corresponds to a daily dose, particularly preferably a daily dose to be used in the evenings.
- the medicament or cosmetic agent is preferably present as a liquid formulation.
- suitable formulations for topical application of the agent are solutions, suspensions, emulsions, microemulsions, nanosystems, creams, gels, lotions, sprays, foams or ointments, and any other formulation which can be applied topically.
- the agent is particularly preferably provided in the form of a cosmetic solution.
- the medicament or cosmetic agent contained in the disposable container according to the invention can have different concentrations of melatonin or of a melatonin derivative.
- the agent preferably contains a concentration of approximately 0.001 to approximately 0.01% (by weight), more preferably approximately 0.003 to 0.004% (by weight) of melatonin or of a melatonin derivative.
- a particularly preferred concentration is approximately 0.0033% (by weight).
- the therapeutic or cosmetic agent contains melatonin or a melatonin derivative as sole active substance.
- the agent can, however, also contain one or more further active substances such as vitamin A, vitamin A acid or other vitamin A derivatives, biotin and/or gingko biloba.
- the medicament or cosmetic agent contains a combination of the active substances melatonin or melatonin derivative with biotin and/or gingko biloba.
- the active substances in this embodiment can be in different dosages.
- a particularly preferred dosage of this combination is from approximately 0.05 to approximately 0.2 mg, particularly preferably approximately 0.1 mg of melatonin or melatonin derivative, from approximately 0.2 to approximately 0.4 mg, particularly preferably approximately 0.3 mg of biotin, and from approximately 1.3 to approximately 1.7 mg, particularly preferably approximately 1.5 mg of gingko biloba.
- Gingko biloba can in this case be contained for example as an extract, in particular as a dry extract, and/or in the form of one or more ingredients.
- the agent contains a combination of the active substances melatonin or melatonin derivative and vitamin A, vitamin A acid or another derivative of vitamin A.
- the dosage of melatonin or melatonin derivative is preferably from approximately 0.05 to 0.2 mg, particularly preferably approximately 0.1 mg of melatonin.
- the medicament or cosmetic agent can also contain one or more cosmetic and/or pharmaceutical auxiliaries or additives, for example thickeners, minerals or perfumes.
- composition according to the invention can be used to promote hair growth, in particular to prevent and/or treat alopecia in men or in women.
- Particularly preferred indications are male pattern androgenetic alopecia, female pattern androgenetic alopecia, male pattern diffuse alopecia and female pattern diffuse alopecia.
- the disposable container according to the invention can contain different volumes of the medicament or cosmetic agent.
- the disposable container contains approximately 2.5 to approximately 3.5 ml, preferably approximately 2.9 to approximately 3.2 ml of the agent.
- a particularly preferred volume is approximately 3.0 ml.
- the therapeutic or cosmetic agent can be filled into the container using any suitable method known in the prior art.
- the agent is preferably filled into the container under GMP conditions. In this way it is possible to ensure that the agent is sterile and that, when the agent is applied, no problems arise in respect of bacterial contamination.
- the disposable container according to the invention can in principle be made of any desired material, in particular a material approved for packaging of food products and pharmaceutical products.
- suitable materials are plastics and mixtures of plastics.
- particularly suitable plastics are polyethylene, polyvinyl chloride, polystyrene, polypropylene, polycycloolefins or mixtures or copolymers thereof, with particular preference being given to polyethylene or polycycloolefins.
- the disposable container can be transparent, non-transparent, colorless or colored. Any desired dyes can for example be added to the plastic in order to obtain a colored container.
- a non-transparent container is preferred for use if the agent contains light-sensitive substances, because a non-transparent container additionally affords protection from light.
- the disposable container according to the invention can in principle have any desired shape. Examples of preferred containers are shown in FIGS. 1 and 2 .
- a suitable disposable container preferably comprises a part in which the agent is contained, and a disposable closure piece which is connected to the lower part via a predetermined break line.
- Simple and safe handling of the container is advantageously ensured by the fact that it preferably has, on its head, a disposable closure piece which is opened by turning it.
- the container can thus be easily opened.
- the agent can emerge only if pressure is applied. This pressure can for example be exerted by hand during the application. This property allows the user to correctly dose the agent and position it in a targeted manner. If the agent is to be applied to the scalp or hair, the opened container can be guided directly through the hair like a comb. This permits straightforward and safe handling of the container and correct dosing of the agent.
- the disposable container carries lettering either printed on or embossed and/or is provided with a label.
- Two or more disposable containers can furthermore be connected to one another in a detachable manner.
- 5 or 10 containers are preferably connected to one another and form an arrangement.
- a container or an arrangement of containers can also be packed, preferably in a lightproof package, particularly preferably in an aluminum bag for example.
- aluminum bag includes bags made of aluminum and also bags which for example are coated with aluminum on the outside or inside.
- bags made of one or more layers of plastic and/or paper can be coated with aluminum.
- a preferred bag comprises, for example, an aluminum-containing laminated foil which additionally includes polyethylene, polyester and/or paper.
- a package in particular a lightproof package, permits storage over a fairly long period of time without loss of efficacy of the agent. Furthermore, such a package can provide protection against gas loss.
- an aluminum bag in which one or more disposable containers are packed can be printed on and/or provided with a label.
- a package unit comprising several arrangements of disposable containers is provided.
- FIGS. 1 and 2 The invention is further explained by attached FIGS. 1 and 2 and examples.
- FIG. 1 shows an arrangement of 5 disposable containers connected to one another in a detachable manner and in a preferred configuration.
- 1 A shows a front view, 1 B a plan view, 1 C a side view, and 1 D a perspective view obliquely from above.
- FIG. 2A shows a front view of an individual disposable container in a preferred configuration.
- 2 B shows a front view of an arrangement of 10 disposable containers connected to one another in a detachable manner
- 2 C shows a side view
- 2 D shows a plan view of said arrangement.
- the composition contains 0.05% by weight of gingko biloba dry extract, 0.01% by weight of biotin, 0.0033% by weight of melatonin and other additives, water, and ethanol.
- the pH of the composition is between 3.5 and 4.
- Example 1 The composition described in Example 1 was tested on 8 healthy female patients in a randomized double-blind study with placebo control and a crossover design.
- the daily dose was 0.1 mg of melatonin (3 ml of the composition) which was applied to the scalp each day before bedtime, for a period of 14 days.
- Urine and blood samples were taken from the patients and were assayed for melatonin and the metabolite 6-hydroxymelatonin sulfate.
- compositions for 14 days did not increase the plasma concentration of melatonin, or the concentration of 6-hydroxymelatonin sulfate in urine, above physiological concentrations.
- Topical application of the melatonin-containing composition was not associated with side effects. Nor were any effects found on reaction times or on cortical excitation parameters.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Packages (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/533,517 US20060035924A1 (en) | 2002-10-30 | 2003-10-30 | Daily melatonin dosing units |
US12/116,484 US8017645B2 (en) | 2002-10-30 | 2008-05-07 | Melatonin daily dosage units |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10250646A DE10250646A1 (de) | 2002-10-30 | 2002-10-30 | Melatonin in kosmetischen Formulierungen |
DE10250646.9 | 2002-10-30 | ||
DE20217814.5 | 2002-11-18 | ||
DE20217814U DE20217814U1 (de) | 2002-11-18 | 2002-11-18 | Melatonin-Tagesdosierungseinheiten |
US10/353,056 US20040094449A1 (en) | 2002-11-18 | 2003-01-29 | Melatonin daily dosage units |
US10/353,056 | 2003-01-29 | ||
PCT/EP2003/012099 WO2004039369A1 (de) | 2002-10-30 | 2003-10-30 | Melatonin-tagesdosierungseinheiten |
US10/533,517 US20060035924A1 (en) | 2002-10-30 | 2003-10-30 | Daily melatonin dosing units |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/353,056 Continuation-In-Part US20040094449A1 (en) | 2002-10-30 | 2003-01-29 | Melatonin daily dosage units |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/116,484 Continuation US8017645B2 (en) | 2002-10-30 | 2008-05-07 | Melatonin daily dosage units |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060035924A1 true US20060035924A1 (en) | 2006-02-16 |
Family
ID=32233793
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/533,517 Abandoned US20060035924A1 (en) | 2002-10-30 | 2003-10-30 | Daily melatonin dosing units |
US10/533,516 Active 2027-10-30 US8062648B2 (en) | 2002-10-30 | 2003-10-30 | Formulations containing melatonin, ginkgo biloba, and biotin |
US12/116,484 Active 2024-07-29 US8017645B2 (en) | 2002-10-30 | 2008-05-07 | Melatonin daily dosage units |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/533,516 Active 2027-10-30 US8062648B2 (en) | 2002-10-30 | 2003-10-30 | Formulations containing melatonin, ginkgo biloba, and biotin |
US12/116,484 Active 2024-07-29 US8017645B2 (en) | 2002-10-30 | 2008-05-07 | Melatonin daily dosage units |
Country Status (21)
Country | Link |
---|---|
US (3) | US20060035924A1 (zh) |
EP (2) | EP1569724B1 (zh) |
JP (2) | JP2006513255A (zh) |
KR (2) | KR20050083836A (zh) |
CN (2) | CN1708331A (zh) |
AT (1) | ATE419038T1 (zh) |
AU (2) | AU2003283327A1 (zh) |
BR (2) | BR0315927A (zh) |
CA (2) | CA2504341A1 (zh) |
DE (1) | DE50311024D1 (zh) |
DK (1) | DK1569724T3 (zh) |
EC (2) | ECSP055819A (zh) |
ES (1) | ES2315541T3 (zh) |
HR (2) | HRP20050386A2 (zh) |
IS (1) | IS7820A (zh) |
MX (2) | MXPA05004537A (zh) |
NO (2) | NO334680B1 (zh) |
NZ (2) | NZ539871A (zh) |
PL (2) | PL224878B1 (zh) |
SI (1) | SI1569724T1 (zh) |
WO (2) | WO2004039369A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008148015A1 (en) * | 2007-05-24 | 2008-12-04 | The Trustees Of Columbia University In The City Of New York | Sustained release formulation of melatonin |
US20100124561A1 (en) * | 2008-11-18 | 2010-05-20 | Studin Joel R | Anti-Aging Product |
US20110130372A1 (en) * | 2008-07-29 | 2011-06-02 | Gaetano Agostinacchio | Composition comprising estrone and hydrocortisone for use in the topical treatment of baldness |
US20200179223A1 (en) * | 2018-12-05 | 2020-06-11 | The Procter & Gamble Company | Container For Personal Health Compositions |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080206353A1 (en) | 2004-12-24 | 2008-08-28 | Jon Phillips | Formulations And Treatments For Trichology |
GB0513581D0 (en) | 2005-07-01 | 2005-08-10 | Norton Healthcare Ltd | Container |
ITGE20070009A1 (it) * | 2007-01-24 | 2008-07-25 | Leila Baeram | Composizione cosmetica e metodo per favorire la ricrescita dei capelli. |
US8940326B2 (en) | 2007-03-19 | 2015-01-27 | Vita Sciences Llc | Transdermal patch and method for delivery of vitamin B12 |
IT1401173B1 (it) * | 2010-07-26 | 2013-07-12 | Lameplast Spa | Contenitore richiudibile per prodotti fluidi, particolarmente per prodotti medicali, farmaceutici e cosmetici |
CN105658223B (zh) | 2014-05-23 | 2018-12-04 | 特里普海尔公司 | 用于减少脱发和/或增加毛发再生的组合物 |
US11696883B2 (en) | 2014-05-23 | 2023-07-11 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
WO2016122172A1 (ko) * | 2015-01-30 | 2016-08-04 | 현대약품 주식회사 | 멜라토닌을 포함하는 안정성이 개선된 육모, 양모 또는 발모 촉진용 조성물 |
US20160361232A1 (en) * | 2015-06-11 | 2016-12-15 | Tokitae Llc | Packaging Multi-Monodose Containers |
US10342735B2 (en) * | 2015-06-11 | 2019-07-09 | Tokitae Llc | Multi-monodose containers |
ES2902842T3 (es) | 2015-07-08 | 2022-03-30 | Triple Hair Inc | Composición que comprende resveratrol y melatonina para reducir la caída y/o aumentar el crecimiento del cabello |
EP3328343B1 (en) * | 2015-07-31 | 2019-07-17 | Isdin, S. A. | Anti-hair loss lotion |
TWI706898B (zh) * | 2015-12-09 | 2020-10-11 | 美商脫其泰有限責任公司 | 包裝能折疊容器的方法 |
KR102142228B1 (ko) * | 2019-12-19 | 2020-08-06 | 홍용익 | 초유, 비오틴 및 과라나 추출물을 함유하는 탈모 방지 및 발모 촉진 효능을 갖는 조성물 및 그의 제조방법 |
KR102644461B1 (ko) * | 2023-08-01 | 2024-03-12 | (주)지에프씨생명과학 | 경피흡수율이 우수한 모발 성장 촉진용 리포좀 조성물 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4654361A (en) * | 1986-01-27 | 1987-03-31 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Method of lowering intraocular pressure using melatonin |
US4746674A (en) * | 1985-08-27 | 1988-05-24 | Cellena (Cell Engineering) Ag | Melatonin compositions and uses thereof |
US5006004A (en) * | 1987-11-25 | 1991-04-09 | The Proctor & Gamble Company | Topical applicator for liquid |
US5577636A (en) * | 1994-06-10 | 1996-11-26 | Yoshida Kogyo Co., Ltd. | Multi-tube container having breakable connections at both ends thereof |
US5952373A (en) * | 1994-12-13 | 1999-09-14 | Beiersdorf Ag | Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides |
US5985293A (en) * | 1996-07-25 | 1999-11-16 | Societe L'oreal S.A. | Antioxidative dermocosmetic compositions comprising very low dosages of melatonin/analogs |
US6281241B1 (en) * | 1999-11-30 | 2001-08-28 | Asat Ag Applied Science And Technology | Use of melatonin for the treatment of androgenetic alopecia |
US20010031744A1 (en) * | 1997-02-04 | 2001-10-18 | Kosbab John V. | Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus |
US20050271692A1 (en) * | 2002-06-25 | 2005-12-08 | Cosmeceutic Solutions Pty. Ltd. | Topical cosmetic compositions |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE7834570U1 (de) | 1978-11-21 | 1979-03-22 | Richardson Merrell Gmbh | Mehrfachpackung |
GB2079238B (en) | 1980-05-12 | 1984-09-05 | Glaxo Group Ltd | Plastics medicament containers |
DK154993C (da) * | 1984-01-17 | 1989-05-29 | Pharmacia As | Beholdersaet bestaaende af et antal til engangsbrug beregnede, tubeformede beholdere, der er indbyrdes forbundet |
US4818540A (en) | 1985-02-25 | 1989-04-04 | Rutgers, The State University Of New Jersey | Transdermal fertility control system and process |
JPS61212512A (ja) * | 1985-03-19 | 1986-09-20 | Shiseido Co Ltd | 養毛料 |
US4651361A (en) * | 1985-10-07 | 1987-03-24 | Nolan William D | Portable combination hair shampoo basin and drying hood |
JPH01242516A (ja) * | 1988-03-24 | 1989-09-27 | Z Lederman Hull | 養毛剤、養毛シャンプー及び養毛促進剤 |
JP2835970B2 (ja) * | 1989-11-20 | 1998-12-14 | 株式会社コーセー | 養毛料 |
JP2636118B2 (ja) * | 1991-09-10 | 1997-07-30 | 三省製薬株式会社 | 育毛剤 |
US5750107A (en) * | 1993-02-12 | 1998-05-12 | Nomura; Manabu | Hair growth promoter |
JPH0853327A (ja) * | 1994-06-10 | 1996-02-27 | Toshihiro Matsumoto | アラントインまたはその誘導体による養毛・育毛剤 |
WO1996016956A1 (fr) † | 1994-12-02 | 1996-06-06 | Kao Corporation | Derives de flavanonol et composition contenant ces derives propre a nourrir les cheveux et a stimuler leur croissance |
DE19509354A1 (de) | 1994-12-08 | 1996-06-13 | Klett Loch Lore M | Kombinationspräparat zur Förderung des Haarwachstums und ggf. des Haut- und Nagelwachstums sowie zur Verhinderung bzw. zur Beseitigung von Haarausfall |
CN2223996Y (zh) | 1995-07-26 | 1996-04-10 | 沈言华 | 清洁灌肠器 |
US6602526B2 (en) * | 1996-02-23 | 2003-08-05 | Medical Doctors Research Institute | Oral compositions containing lotus |
JP2001518923A (ja) | 1997-03-26 | 2001-10-16 | ダブリュ エイチ エム マーカス,フランシスカス | 鼻腔用メラトニン組成物 |
EP0867181A1 (en) * | 1997-03-26 | 1998-09-30 | Franciscus Wilhelmus Henricus Maria Merkus | Nasal melatonin composition |
JPH10283531A (ja) * | 1997-03-31 | 1998-10-23 | Toshiba Corp | 現金処理システム |
JPH10287531A (ja) * | 1997-04-14 | 1998-10-27 | Kose Corp | 毛髪用化粧料 |
JPH11180833A (ja) * | 1997-12-16 | 1999-07-06 | Shiseido Co Ltd | 頭皮頭髪用組成物 |
US6030948A (en) † | 1997-12-19 | 2000-02-29 | Mann; Morris A. | Hair regeneration compositions for treatment of alopecia and methods of application related thereto |
US6524619B2 (en) | 2000-01-27 | 2003-02-25 | Chronorx, Inc. | Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus |
US6596266B2 (en) | 2000-02-18 | 2003-07-22 | Natural Science, Inc. | Compositions containing minoxidil and saw palmetto for treating baldness |
DE10035735C2 (de) * | 2000-07-22 | 2003-02-20 | Wella Ag | Haartonikum zur Vorbeugung oder Behandlung von Haarausfall |
JP2002050328A (ja) * | 2000-08-02 | 2002-02-15 | Seiko Instruments Inc | 非水電解質二次電池 |
GB0019327D0 (en) * | 2000-08-08 | 2000-09-27 | Buchanan Baillie Hamilton Paul | Slimming system |
DE20019365U1 (de) | 2000-11-15 | 2001-01-18 | Mann Gerhard Chem Pharm Fab | Eindosis-Kunststoffbehältnis zur Aufnahme von einem flüssigen oder gelartigen pharmazeutischen Präparat |
DE10110418A1 (de) | 2001-03-05 | 2002-09-12 | Asat Ag Applied Science & Tech | Melatonin-Vitamin-A-Präparate |
US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
WO2003049687A2 (en) | 2001-12-06 | 2003-06-19 | Weller Health, Inc. | Medicinal compositions & therapeutic methods |
US6956266B1 (en) * | 2004-09-09 | 2005-10-18 | International Business Machines Corporation | Structure and method for latchup suppression utilizing trench and masked sub-collector implantation |
-
2003
- 2003-10-30 BR BR0315927-2A patent/BR0315927A/pt not_active IP Right Cessation
- 2003-10-30 CN CNA2003801023960A patent/CN1708331A/zh active Pending
- 2003-10-30 KR KR1020057007281A patent/KR20050083836A/ko not_active Application Discontinuation
- 2003-10-30 CN CNA200380102359XA patent/CN1708301A/zh active Pending
- 2003-10-30 EP EP03775265A patent/EP1569724B1/de not_active Expired - Lifetime
- 2003-10-30 JP JP2005501814A patent/JP2006513255A/ja active Pending
- 2003-10-30 JP JP2005501815A patent/JP2006510556A/ja active Pending
- 2003-10-30 WO PCT/EP2003/012099 patent/WO2004039369A1/de active Application Filing
- 2003-10-30 US US10/533,517 patent/US20060035924A1/en not_active Abandoned
- 2003-10-30 PL PL376226A patent/PL224878B1/pl unknown
- 2003-10-30 EP EP03769477.5A patent/EP1562585B2/de not_active Expired - Lifetime
- 2003-10-30 CA CA002504341A patent/CA2504341A1/en not_active Abandoned
- 2003-10-30 AU AU2003283327A patent/AU2003283327A1/en not_active Abandoned
- 2003-10-30 AT AT03775265T patent/ATE419038T1/de active
- 2003-10-30 WO PCT/EP2003/012097 patent/WO2004039454A1/de not_active Application Discontinuation
- 2003-10-30 ES ES03775265T patent/ES2315541T3/es not_active Expired - Lifetime
- 2003-10-30 PL PL375507A patent/PL212984B1/pl unknown
- 2003-10-30 AU AU2003278164A patent/AU2003278164A1/en not_active Abandoned
- 2003-10-30 DK DK03775265T patent/DK1569724T3/da active
- 2003-10-30 MX MXPA05004537A patent/MXPA05004537A/es active IP Right Grant
- 2003-10-30 NZ NZ539871A patent/NZ539871A/en unknown
- 2003-10-30 US US10/533,516 patent/US8062648B2/en active Active
- 2003-10-30 BR BR0315878-0A patent/BR0315878A/pt not_active IP Right Cessation
- 2003-10-30 SI SI200331508T patent/SI1569724T1/sl unknown
- 2003-10-30 DE DE50311024T patent/DE50311024D1/de not_active Expired - Lifetime
- 2003-10-30 MX MXPA05004535A patent/MXPA05004535A/es active IP Right Grant
- 2003-10-30 CA CA002504361A patent/CA2504361A1/en not_active Abandoned
- 2003-10-30 NZ NZ539872A patent/NZ539872A/en unknown
- 2003-10-30 KR KR1020057007293A patent/KR100849916B1/ko not_active IP Right Cessation
-
2005
- 2005-04-25 IS IS7820A patent/IS7820A/is unknown
- 2005-04-29 HR HR20050386A patent/HRP20050386A2/xx not_active Application Discontinuation
- 2005-04-29 HR HR20050385A patent/HRP20050385A2/xx not_active Application Discontinuation
- 2005-05-24 NO NO20052494A patent/NO334680B1/no not_active IP Right Cessation
- 2005-05-24 NO NO20052490A patent/NO335547B1/no not_active IP Right Cessation
- 2005-05-26 EC EC2005005819A patent/ECSP055819A/es unknown
- 2005-05-26 EC EC2005005820A patent/ECSP055820A/es unknown
-
2008
- 2008-05-07 US US12/116,484 patent/US8017645B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4746674A (en) * | 1985-08-27 | 1988-05-24 | Cellena (Cell Engineering) Ag | Melatonin compositions and uses thereof |
US4654361A (en) * | 1986-01-27 | 1987-03-31 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Method of lowering intraocular pressure using melatonin |
US5006004A (en) * | 1987-11-25 | 1991-04-09 | The Proctor & Gamble Company | Topical applicator for liquid |
US5577636A (en) * | 1994-06-10 | 1996-11-26 | Yoshida Kogyo Co., Ltd. | Multi-tube container having breakable connections at both ends thereof |
US5952373A (en) * | 1994-12-13 | 1999-09-14 | Beiersdorf Ag | Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides |
US5985293A (en) * | 1996-07-25 | 1999-11-16 | Societe L'oreal S.A. | Antioxidative dermocosmetic compositions comprising very low dosages of melatonin/analogs |
US20010031744A1 (en) * | 1997-02-04 | 2001-10-18 | Kosbab John V. | Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus |
US6281241B1 (en) * | 1999-11-30 | 2001-08-28 | Asat Ag Applied Science And Technology | Use of melatonin for the treatment of androgenetic alopecia |
US20050271692A1 (en) * | 2002-06-25 | 2005-12-08 | Cosmeceutic Solutions Pty. Ltd. | Topical cosmetic compositions |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008148015A1 (en) * | 2007-05-24 | 2008-12-04 | The Trustees Of Columbia University In The City Of New York | Sustained release formulation of melatonin |
US20100120887A1 (en) * | 2007-05-24 | 2010-05-13 | The Trustees Of Columbia University In The City Of New York | Sustained release formulation of melatonin |
US20110130372A1 (en) * | 2008-07-29 | 2011-06-02 | Gaetano Agostinacchio | Composition comprising estrone and hydrocortisone for use in the topical treatment of baldness |
US20100124561A1 (en) * | 2008-11-18 | 2010-05-20 | Studin Joel R | Anti-Aging Product |
WO2010059547A2 (en) * | 2008-11-18 | 2010-05-27 | Studin Joel R | Anti-aging product |
WO2010059547A3 (en) * | 2008-11-18 | 2010-10-07 | Studin Joel R | Anti-aging product |
US9393182B2 (en) | 2008-11-18 | 2016-07-19 | Scarguard Labs, Llc | Anti-aging product |
US20200179223A1 (en) * | 2018-12-05 | 2020-06-11 | The Procter & Gamble Company | Container For Personal Health Compositions |
US11877981B2 (en) * | 2018-12-05 | 2024-01-23 | The Procter & Gamble Company | Container for personal health compositions |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8017645B2 (en) | Melatonin daily dosage units | |
US5196001A (en) | Devices and methods for preparing pharmaceutical solutions | |
BRPI1010958B1 (pt) | acondicionamento termoformado, sua utilização e seu método de fabricação | |
JP2003512107A (ja) | 医薬品のパッケージ及びパッケージを製造し、滅菌する方法 | |
IL168287A (en) | Disposable medicament/cosmetic container for topical application and arrangements and package units comprising the same | |
CA3034839A1 (en) | Methods and compositions for treating cutaneous fungal infections | |
US20040094449A1 (en) | Melatonin daily dosage units | |
US20060182790A1 (en) | Dermal medicaments application enhancer | |
US20080073350A1 (en) | Assemblies for dispensing material, systems and kits including the assemblies, and methods of using and forming same | |
ES2353865T3 (es) | Unidades de dosificación diaria de melatonina. | |
US9393182B2 (en) | Anti-aging product | |
CA2015111A1 (en) | New binary dispensor for the application of fluids, semi-fluids or semi-solids | |
KR950006561Y1 (ko) | 일회용 의약품 및 위생용품이 구비된 구급약품 | |
SK500592021U1 (sk) | Súprava obsahujúca biologicky aktívny prípravok | |
Rudresh | Development of transdermal drug delivery System for diclofenac sodium | |
CN107690325A (zh) | 双腔室分配装置 | |
KR920700041A (ko) | 치료화합물과 그의 조성 및 용도 | |
KR20070020421A (ko) | 각질 조직의 처리 | |
TWM468493U (zh) | 乾溼分離之敷膜包裝袋 | |
TH23425A (th) | สารสูตรผสมยาแอโรโซล | |
TH18176A (th) | อิมัลชันชนิดน้ำมัน-ใน-น้ำ | |
CZ6245U1 (cs) | Dávkovač léků |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASAT AG APPLIED SCIENCE & TECHNOLOGY, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHMID, HANS W.;REEL/FRAME:016645/0421 Effective date: 20050606 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |